Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Akesobio

Akeso, Inc.
康方生物科技(開曼)有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

VOLUNTARY ANNOUNCEMENT

SHARE PURCHASE PURSUANT TO THE 2021 RESTRICTED SHARE UNIT SCHEME

This announcement is made by Akeso, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest developments of the Group.

Reference is made to the announcement of the Company dated December 7, 2021 (the "**Announcement**") in relation to the adoption of the 2021 Restricted Share Unit Scheme on December 6, 2021 (the "**2021 RSU Scheme**"). Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

On December 13, 2021, the Trustee purchased a total number of 200,000 Shares (the "**Share Purchase**") on the market for the purpose of the 2021 RSU Scheme as a long-term equity incentive for employees in the future. Details of the Shares purchased and the latest information about the Shares held by Trustee on trust for the benefit of the Selected Participants are as follows:

Trade date:	December 13, 2021
Settlement date:	December 15, 2021
Total number of Shares purchased:	200,000 Shares
Percentage of the Shares purchased to the total number of Shares in issue as at the date of this announcement:	Approximately 0.024%
Consideration per Share:	Approximately HK$40.00 to HK$42.00

Total consideration of Shares purchased (excluding all related expenses, transaction levy, brokerage, tax, duties and levies):	Approximately HK$8,000,000
Balance of number of Shares held by the Trustee:	
— Prior to the Share Purchase (Percentage to the total number of Shares in issue as at the date of this announcement)	250,000 Shares (approximately 0.031%)
— Immediately after the Share Purchase (Percentage to the total number of Shares in issue as at the date of this announcement)	450,000 Shares (approximately 0.055%)

The Share Purchase was funded by the Company's own financial resources other than proceeds from the listing of the Shares on the Main Board of the Stock Exchange.

As at the date of this announcement, no RSUs have been granted to any Selected Participants pursuant to the 2021 RSU Scheme. The Board will determine at its absolute discretion such number of RSUs to be granted to the Selected Participants under the 2021 RSU Scheme with such vesting criteria and conditions as it may deem appropriate.

By Order of the Board
Akeso, Inc.
Dr. XIA Yu
Chairwoman and executive director

Hong Kong, December 14, 2021

As at the date of this announcement, the Board of the Company comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive directors, Mr. XIE Ronggang and Dr. ZHOU Yi as non-executive directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.